Addiction treatment in Washington

On any given week in Washington, several hundred residents are hospitalized for overdose. The treatment infrastructure that could prevent most of the deaths behind those hospitalizations is distributed unevenly — 471 facilities concentrated in specific metros, thinning as you move toward the Pacific Northwest geography. This is an editorial look at who that serves and who it fails.

The Medicaid question

Medicaid: Washington expanded Medicaid in 2014 under the Affordable Care Act. The word "Medicaid" carries different weight in Washington than in a neighboring state with the opposite policy. Has realistic access to Medicaid coverage for addiction treatment once enrolled — and the population that falls outside coverage has to work harder, wait longer, and sometimes simply does without.

The overdose-mortality context

At 28.0 per 100,000 in Washington, overdose mortality ranks within a specific band of the national distribution. fentanyl accounts for most fatalities, with fentanyl contamination driving the trajectory; the places where the most deaths happen and the places where the most treatment is funded are often not the same places. The specific context: Seattle fentanyl mortality paired with east-of-Cascades rural provider shortage.

How access actually works in Washington

Inside the 471 licensed facilities in Washington, the clinical quality variation is substantial. The practical context here is that Seattle fentanyl mortality paired with east-of-Cascades rural provider shortage — which is why the difference between a well-run IOP and a fee-for-service residential chain that churns patients through 30-day cycles is not visible from the outside. It becomes visible when you ask the specific question: "Does this program offer buprenorphine for opioid use disorder?"

What to do next

The next productive step for most Washington residents considering treatment is boringly practical: call a primary-care doctor. PCPs now routinely prescribe buprenorphine, can initiate MAT, and have access to referral networks that the patient-brokering side of the industry does not feed on. A PCP visit costs less and produces fewer surprises than a direct call to a treatment facility's admissions line.